Log In
BCIQ
Print this Print this
 

AEZS-129

  Manage Alerts
Collapse Summary General Information
Company Aeterna Zentaris Inc.
DescriptionOral phosphoinositide 3-kinase (PI3K) inhibitor
Molecular Target Phosphoinositide 3-kinase (PI3K)
Mechanism of ActionPhosphoinositide 3-kinase (PI3K) inhibitor
Therapeutic Modality 
Latest Stage of DevelopmentPreclinical
Standard Indication Cancer (unspecified)
Indication DetailsTreat cancer
Regulatory Designation
Partner

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
 Deals Details
Get a free BioCentury trial today